Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Change In Receivables : $-1.27 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Change In Receivables?

Infant Bacterial Therapeutics AB's change in receivables for the quarter that ended in Mar. 2024 was $-1.65 Mil. It means Infant Bacterial Therapeutics AB's Accounts Receivable increased by $1.65 Mil from Dec. 2023 to Mar. 2024 .

Infant Bacterial Therapeutics AB's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.91 Mil. It means Infant Bacterial Therapeutics AB's Accounts Receivable increased by $0.91 Mil from Dec. 2022 to Dec. 2023 .

Infant Bacterial Therapeutics AB's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Infant Bacterial Therapeutics AB's liquidation value for the three months ended in Mar. 2024 was $22.87 Mil.

Infant Bacterial Therapeutics AB Change In Receivables Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Change In Receivables Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.29

-0.55

0.48

0.69

-0.91

Infant Bacterial Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-1.28	0.96	-0.30	-0.29	-1.65

Infant Bacterial Therapeutics AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.27 Mil.

Infant Bacterial Therapeutics AB (GREY:IFTBF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Infant Bacterial Therapeutics AB's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Infant Bacterial Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

Infant Bacterial Therapeutics AB's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	29.739	-	6.871	+	0.75 * 0	+	0.5 * 0
=	22.87

Infant Bacterial Therapeutics AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden 9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines